There are other reasons to pay attention to Viking Therapeutics.
(NASDAQ: VERX) (“Vertex” or the “Company”) , the Decision-to-Defense™ global indirect tax and compliance company, today released new research pointing to a structural shift in how global enterprises ...
18d
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
Atumelnant is a once-daily pill that has been well-tolerated in trials without serious adverse events and which helped bring ...
Vertex CEO Chris Young told Jon Fortt tax compliance is being remade by AI, e-invoicing mandates and agentic commerce – but ...
Vertex, Inc. ( (VERX)) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors. Take advantage of TipRanks Premium at 50% off! Unlock powerful ...
The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to ...
Perhaps the biggest asset Crinetics brings is a drug called PALSONIFY -- the first and only once-daily oral therapy approved for adults with acromegaly. It won U.S. approval in September 2025 and was ...
Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...
Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market ...
AbCellera’s T-cell engager (TCE) platform has reeled in a second client this summer, with Vertex Pharmaceuticals ...
Biogen has found a successor to longtime legal chief Susan Alexander, tapping former Vertex Pharmaceuticals executive and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results